Notícias e Atividades da Monte Rosa Therapeutics

Monte Rosa Therapeutics é uma das ...

• Russell 3000;
• TOB Iconic 10,000.

Monte Rosa Therapeutics é uma empresa listada sob o símbolo GLUE (US).

Veja o organograma con seus 23 executivos principais

Biografias mais buscadas da Monte Rosa Therapeutics

• Markus Warmuth, Chief Executive Officer and Director
• Eric Hughes, Director
• Chandra Leo, Director

Criar um alerta
para seguir os movimentos de executivos da Monte Rosa Therapeutics.

Monte Rosa Therapeutics possui 2.405 concorrentes concorrentes Eurofins (Luxemburgo), Lonza (Suíça) e BioNTech (Alemanha).

Popular M&A news in Biotecnologia

• IMU Biosciences acaba de anunciar uma arrecadação de fundos de 53 milhões de dólares. (publicado em 3 de junho de 2026).
• NewLimit acaba de anunciar uma arrecadação de fundos de 435 milhões de dólares. (publicado em 3 de junho de 2026).
• Rallybio and Avenzo Therapeutics have announced they will merge  (publicado em 1 de junho de 2026)..

Outros contatos sugeridos na indústria do Biotecnologia

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer da Inceptive
• Jan Van de Winkel - President and Chief Executive Officer da Genmab
• Valerie Hanote - Non-Executive Director da Eurofins

Saiba mais sobre a indústria do Biotecnologia

Últimos comunicados de imprensa de Monte Rosa Therapeutics

• Monte Rosa Therapeutics to Participate in the Jefferies Global Healthcare Conference - Monte Rosa Therapeutics
• Monte Rosa Therapeutics Announces First Quarter 2025 Financial Results and Business Updates - Monte Rosa Therapeutics
• Monte Rosa Therapeutics Announces Fourth Quarter 2024 Financial Results and Provides Corporate Update Including New Clinical Results from MRT-6160 and MRT-2359 Programs - Monte Rosa Therapeutics
• Monte Rosa Therapeutics to Present Pipeline Update and Release Fourth Quarter and Full Year 2024 Financial Results on March 20, 2025 - Monte Rosa Therapeutics
• Monte Rosa Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference - Monte Rosa Therapeutics
• Monte Rosa Therapeutics Provides Corporate Update and Key Anticipated Milestones for 2025 - Monte Rosa Therapeutics
• Monte Rosa Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - Monte Rosa Therapeutics
• Monte Rosa Therapeutics Presents Preclinical Data at the 2024 San Antonio Breast Cancer Symposium on the Potential of its CDK2-directed Molecular Glue Degraders to Treat HR-positive/HER2-negative Breast Cancer - Monte Rosa Therapeutics
• Monte Rosa Therapeutics Appoints Dr. Eric A. Hughes to Board of Directors - Monte Rosa Therapeutics
• Monte Rosa Therapeutics Provides Development Progress Update for Ongoing MRT-2359 Phase 1/2 Study in Patients with MYC-driven Solid Tumors - Monte Rosa Therapeutics
• View more press releases Close

Redes sociais sobre Monte Rosa Therapeutics

• Monte Rosa Therapeutics na Wikipedia, Google News e Yahoo Finance
• Monte Rosa Therapeutics na LinkedIn, X (Twitter) e YouTube